文献速递乳腺癌支持与姑息治疗

MA.17R 试验:来曲唑辅助治疗延长至10年的生活质量分析

Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.
PubMed 文献 · J Clin Oncol · 2018-01-12

MA.17R 是加拿大癌症试验组领导的 III 期随机对照试验,比较激素受体阳性乳腺癌患者完成5年内分泌治疗后继续来曲唑与安慰剂的疗效,生活质量为次要终点。结果显示两组 SF-36 总分及 MENQOL 各领域均无临床显著差异,仅 role-physical 亚量表有差异。

要点

  • 延长来曲唑至10年未导致总体生活质量下降。
  • SF-36 躯体与心理总分变化两组间无差异。
  • MENQOL 四个症状领域两组间均无差异。

核心结论

  • 来曲唑组与安慰剂组在 SF-36 总结分及 MENQOL 上无临床显著差异,提示继续芳香化酶抑制剂治疗未伴随总体生活质量恶化。

研究设计与样本

  • 加拿大癌症试验组领导的 III 期随机对照试验,比较5年芳香化酶抑制剂辅助治疗后来曲唑与安慰剂,生活质量为次要终点。

主要发现

  • SF-36 躯体成分总结基线均分来曲唑组47.5、安慰剂组47.9,心理成分总结来曲唑组55.5、安慰剂组54.8,接近人群常模50。
  • 两组 SF-36 躯体与心理成分总结及其他8个生活质量领域的平均变化评分均无差异,仅 role-physical 亚量表有差异。
  • MENQOL 四个症状领域均未发现差异。

临床怎么用

  • 对于已完成5年辅助内分泌治疗的激素受体阳性乳腺癌患者,延长来曲唑至10年未显示总体生活质量恶化,可作为医患沟通依据。

局限性

  • 生活质量评估在非加拿大中心为可选,可能影响样本代表性。
  • 原文未报告 role-physical 亚量表差异的具体数值与临床意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose MA.17R was a Canadian Cancer Trials Group-led phase III randomized controlled trial comparing letrozole to placebo after 5 years of aromatase inhibitor as adjuvant therapy for hormone receptor-positive breast cancer. Quality of life (QOL) was a secondary outcome measure of the study, and here, we report the results of these analyses. Methods QOL was measured using the Short Form-36 (SF-36; two summary scores and eight domains) and menopause-specific QOL (MENQOL; four symptom domains) at baseline and every 12 months up to 60 months. QOL assessment was mandatory for Canadian Cancer Trials Group centers but optional for centers in other groups. Mean change scores from baseline were calculated. Results One thousand nine hundred eighteen women were randomly assigned, and 1,428 women completed the baseline QOL assessment. Compliance with QOL measures was > 85%. Baseline summary scores for the SF-36 physical component summary (47.5 for letrozole and 47.9 for placebo) and mental component summary (55.5 for letrozole and 54.8 for placebo) were close to the population norms of 50. No differences were seen between groups in mean change scores for the SF-36 physical and mental component summaries and the other eight QOL domains except for the role-physical subscale. No difference was found in any of the four domains of the MENQOL Conclusion No clinically significant differences were seen in overall QOL measured by the SF-36 summary measures and MENQOL between the letrozole and placebo groups. The data indicate that continuation of aromatase inhibitor therapy after 5 years of prior treatment in the trial population was not associated with a deterioration of overall QOL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lemieux J, Brundage MD, Parulekar WR, et al. Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. J Clin Oncol. 2018. PMID: 29328860. doi:10.1200/JCO.2017.75.7500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。